Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gushukang is a traditional Chinese herbal compound medicine approved and widely used in China for the prevention and treatment of osteoporosis. It is formulated from multiple herbs, including Herba Epimedii, Rehmannia glutinosa, and Rhizoma Drynariae. The drug acts by promoting osteoblast differentiation (bone formation) and inhibiting osteoclast differentiation (bone resorption), thereby increasing bone mineral density. Mechanistic studies suggest that its effects are mediated through modulation of calcium homeostasis and activation of the BMP-2/Smads signaling pathway. Additionally, it has been shown to induce type-H vessel formation in bone tissue via upregulation of hypoxia inducible factor-1 alpha (HIF-1α), contributing to improved bone vascularization and health[5][6][1]. Clinical studies have demonstrated efficacy in both primary osteoporosis and postmenopausal osteoporosis[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gushukang.